FDA approves new cancer treatments and psychedelic therapy pathways while court blocks mail abortion drugs; healthcare system reforms and innovative diabetes research advance

A U.S. appeals court temporarily blocked federal rules allowing mifepristone abortion drugs to be dispensed through the mail, significantly restricting access to medication abortion services.

FDA authorized expanded access treatment for daraxonrasib, an oral RAS(ON) inhibitor that doubled survival rates for metastatic pancreatic cancer patients in phase 3 trials.

Vepdegestrant received FDA approval for treating ESR1-mutated breast cancer based on phase 3 VERITAC-2 trial results showing significantly improved progression-free survival.

A new FDA regulatory pathway could accelerate approval of psychedelic therapies for treatment-resistant depression and PTSD, with psilocybin from Compass Pathways emerging as a leading candidate for first approval.

Royal College of Physicians survey reveals nearly half of specialist doctors express uncertainty about their role in NHS neighbourhood health teams, raising concerns about healthcare system integration.

Researchers proposed a new staging classification system for advanced cutaneous squamous cell carcinoma that better differentiates disease progression from mortality outcomes compared to current standards.

Sirolimus-eluting balloon catheters show comparable performance to standard care for repeat coronary in-stent restenosis at one year, though drug-eluting stents remain superior for single-layer disease.

Scientists created living 'cyborg' organoids by combining electronic sensors with human islet cells, enabling detailed monitoring of islet cell function and advancing potential diabetes treatment approaches.